FDA Investigator

Jacqueline M Diaz Albert

Latest inspection on record: Philadelphia, United States, March 2022 · records back to 2008

BiologicsHuman Drugs

FDA inspection record · Last updated July 12, 2026

Overview

  • 96 inspections across 81 sites are on record.
  • 72 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2022-03-04.

At a glance

Inspections

96

Sites

81

Observations

72

Career since

Jan 2008

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Spark Therapeutics, Inc.4 Mar 2022BiologicsOn file
Grifols Diagnostic Solutions, Inc.7 Dec 2021BiologicsOn file
Nelson Laboratories, LLC9 Nov 2021Biologics
Janssen Pharmaceuticals Inc.17 Sep 2021Biologics
Jubilant HollisterStier LLC31 Aug 2021BiologicsOn file

Sites inspected

Spark Therapeutics, Inc.Philadelphia, United States1 insp.
Grifols Diagnostic Solutions, Inc.Emeryville, United States1 insp.
Nelson Laboratories, LLCSalt Lake City, United States1 insp.
Janssen Pharmaceuticals Inc.Raritan, United States1 insp.
Jubilant HollisterStier LLCSpokane, United States1 insp.

Co-investigators

Investigators who share inspections with this person.

Paula A Trost15 shared
Jacqueline M Diaz Albertini7 shared

Full investigator report

Get the verbatim findings behind Jacqueline M Diaz Albert's 72 observations

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site